Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

KALEIDO BIOSCIENCES, INC.

(KLDO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kaleido Biosciences : Says Bowel Disease Drug Trial Meets Primary Safety Endpoint

10/05/2021 | 07:59am EST


ę MT Newswires 2021
All news about KALEIDO BIOSCIENCES, INC.
11/15Kaleido Biosciences to Participate in the Piper Sandler 33rd Annual Virtual Healthcare ..
GL
11/12Chardan Adjusts Price Target on Kaleido Biosciences to $11 From $15 on Pipeline Assets ..
MT
11/10Kaleido Biosciences to Appoint Dr. Alison Long as Chief Medical Officer
GL
11/10Kaleido Biosciences, Inc. to Appoint Alison Long as Chief Medical Officer, Effective De..
CI
11/03JMP Securities Adjusts Price Target on Kaleido Biosciences to $22 From $25, Maintains M..
MT
11/01KALEIDO BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
11/01Press Release issued by Kaleido Biosciences, Inc., dated November 1, 2021, furnished he..
PU
11/01Kaleido Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
11/01Kaleido Biosciences Reports Third Quarter 2021 Financial Results
AQ
10/20NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
More news
Analyst Recommendations on KALEIDO BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 1,61 M - -
Net income 2021 -94,6 M - -
Net cash 2021 5,83 M - -
P/E ratio 2021 -1,62x
Yield 2021 -
Capitalization 155 M 155 M -
EV / Sales 2021 93,2x
EV / Sales 2022 173x
Nbr of Employees 82
Free-Float 91,0%
Chart KALEIDO BIOSCIENCES, INC.
Duration : Period :
Kaleido Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KALEIDO BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 3,65 $
Average target price 14,80 $
Spread / Average Target 305%
EPS Revisions
Managers and Directors
Daniel L. Menichella President, Chief Executive Officer & Director
William E. Duke Chief Financial Officer
Theo Melas-Kyriazi Chairman
Johan van Hylckama Vlieg Chief Scientific Officer
Kimberly Hocknell Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
KALEIDO BIOSCIENCES, INC.-56.04%170
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.81%24 431